Work

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-150743

Authors: Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Institutions: The University of Texas MD Anderson Cancer Center, Abramson Cancer Center, University of Pennsylvania, Norton Healthcare, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Weill Cornell Medicine, Mayo Clinic, Hackensack Meridian Health, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, Los Angeles, University of Miami, Sylvester Comprehensive Cancer Center, Astellas Pharma (United States), Genentech, AbbVie (United States), Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3213057375

Cites:

Cited by: 11

Related to: 10